Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer
about
Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinomaExploring circulating micro-RNA in the neoadjuvant treatment of breast cancerFifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)Translating neoadjuvant therapy into survival benefits: one size does not fit all.Adjuvant breast cancer chemotherapy during late-trimester pregnancy: not quite a standard of careOptimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.Triple-negative breast cancer: role of specific chemotherapy agentsPredictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy.A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer.Designing adjuvant treatment based on biological measurements in the neoadjuvant settingDecreased FOXF2 mRNA expression indicates early-onset metastasis and poor prognosis for breast cancer patients with histological grade II tumor.Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.The changing role of pathology in breast cancer diagnosis and treatment.EPMA position paper in cancer: current overview and future perspectives.Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working groupPre-operative systemic therapy in locally advanced breast cancer: a single institution experience.Allelic imbalance at the HER2/TOP2A locus in breast cancerPilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast CancerNeoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled TrialsTumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapyThe prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancerPredictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer.Correlation between the expression of S100A4 and the efficacy of TAC neoadjuvant chemotherapy in breast cancer.Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis.Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancerWeekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant TherapyMorphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival: a single center observational studyA case of synchronous bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character.Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer.Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months.
P2860
Q25256293-7450FCA1-B5E9-47A9-A91B-C0782E117A9FQ28066481-2E5D3414-EC23-48C2-82A0-E9463E017F0EQ28270514-E449B09D-B0E4-4D73-9D10-C6CBC1AC442CQ30251738-F2D91B4C-A494-46A5-B286-2D1C572BC65AQ33286192-90A6EC90-556C-4B5A-8732-FE667634E9AFQ33698446-207093F3-1F13-49CB-A23E-0A941FF23CDEQ33843830-BE176F95-A0A1-4BE5-947E-73713936B003Q33900930-EDA0EA4F-9AE3-4690-8305-0965A831438DQ34059719-10BCBB29-7203-498C-9240-992ED1C2C95EQ34207279-708AD4EE-FE94-4CCD-9182-820616DC8486Q34423533-56B6B253-8E2B-4D37-9950-6CA09963E075Q34689061-C0D326A1-474F-4B19-9A88-6DCC1B130CBFQ34779690-D0A64BD4-9E21-443E-80F0-32D231E893B8Q35082260-51827747-2068-4183-A94F-43037D94FF4CQ35532215-6559AE66-E957-4621-AB65-4F610010E840Q35552069-4F4C55FA-515C-4B73-8675-C2990BB4CA44Q35572926-88FAF0E3-6E19-4048-8C6C-5C0B5E2D1790Q35663036-5A214D5A-8240-4AF2-B2EF-88FA9AF8BAF1Q35671180-BB1F6864-E738-4AC9-8DC9-15451DD9AF40Q35862343-49A8A4E1-4C29-4110-A8F7-00B1D5A6A924Q35881780-E7414706-5B4E-46A4-9961-90B6B895DB9FQ35889643-008C4C7D-C950-47EB-A3E5-98189CBEDB79Q35899068-56B31AA4-32C2-41D5-86CA-84572D04418DQ36092031-692FA134-D43B-4AD1-AC04-9E209983CADAQ36134671-893A57F0-A74C-47BD-86F5-913FC4DEB11FQ36225020-2D48D09B-F71E-45A7-AD28-379AEE55E169Q36334801-4E2E964C-6493-4A4D-AC6D-578F3478DEE7Q36458775-386C2632-2C09-46CD-99C9-9EF54C8A0944Q36551617-D79762AA-C733-4D27-90C6-D9B6C84EF8FDQ36611182-6529E748-B368-49EC-AFF9-8A7060E0BF43Q36612439-164D29A3-ED25-4FB0-ACF4-BBF22754C074Q36853593-55C89158-89A8-499A-8C26-FB2D974FC56FQ36868191-38F4788B-8009-4DFA-9395-A14AACB1D653Q36965404-37B28DEC-319F-4814-BF15-3CAF772C8D9BQ36977587-77437FDE-F9B6-45EC-8A5B-E01BDF05251DQ37032851-534BED39-42E0-4BDE-ABA2-8A318340C728Q37176151-7D6A4BBF-39FB-41A5-BF82-43ECD2F7C7B9Q37309678-8840FC4E-43B3-4696-BF91-4C826D239452Q37394443-9B8C0BEB-B3A9-469D-9155-55536110686FQ37405890-1C594173-6F6A-425B-93E0-5066EAC05EA0
P2860
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Oestrogen receptor status, pat ...... herapy for early breast cancer
@ast
Oestrogen receptor status, pat ...... herapy for early breast cancer
@en
type
label
Oestrogen receptor status, pat ...... herapy for early breast cancer
@ast
Oestrogen receptor status, pat ...... herapy for early breast cancer
@en
prefLabel
Oestrogen receptor status, pat ...... herapy for early breast cancer
@ast
Oestrogen receptor status, pat ...... herapy for early breast cancer
@en
P2093
P2860
P356
P1476
Oestrogen receptor status, pat ...... herapy for early breast cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602235
P407
P577
2004-12-01T00:00:00Z